Á¦12Â÷ ´ëÇÑÁ¾¾ç³»°úÇÐȸ Çмú´ëȸ ¹× 2019 ±¹Á¦Çмú´ëȸ : 2019-11-07±³À°ÀÏÀÚ : 2019-11-07
±³À°Àå¼Ò : µå·¡°ï¾¾Æ¼ ÇѶó·ë ¿Ü
±³À°ÁÖÁ¦ :
Á¦12Â÷ ´ëÇÑÁ¾¾ç³»°úÇÐȸ Çмú´ëȸ ¹× 2019 ±¹Á¦Çмú´ëȸÁÖÃÖ±â°ü : ´ëÇÑÁ¾¾ç³»°úÇÐȸ(17.5 ¸íĪº¯°æ Çѱ¹ÀÓ»ó¾ÏÇÐȸ)
´ã´çÀÚ : °ÇØÁø
¿¬¶ôó : 02-735-2857
À̸ÞÀÏ :
ksmo3@ksmo.or.kr ±³À°Á¾·ù : ³»°ú, ¹æ»ç¼±Á¾¾çÇаú, º´¸®°úÀÇ·áÁ¤Ã¥
Âü¼®¿¹»óÀοø : 1000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 28 ½Ã°£ 40ºÐ
¼¼ºÎ¼ö°·á : 170,000¿ø
ºñ°í ±³¼ö/Àü¹®ÀÇ/ÀüÀÓÀÇ(Çб³¹×º´¿ø) - ȸ¿ø »çÀü 100,000¿ø ÇöÀå 120,000¿ø ±³¼ö/Àü¹®ÀÇ/ÀüÀÓÀÇ(Çб³¹×º´¿ø) - ºñȸ¿ø »çÀü 120,000¿ø ÇöÀå 150,000¿ø Àü°øÀÇ/°£È£»ç/¾à»ç/±ºÀÇ°ü/Çлý - ȸ¿ø »çÀü 50,000¿ø ÇöÀå 70,000¿ø Àü°øÀÇ/°£È£»ç/¾à»ç/±ºÀÇ°ü/Çлý -ºñȸ¿ø »çÀü 70,000¿ø ÇöÀå 90,000¿ø ±â¾÷/±âŸ - ȸ¿ø »çÀü 100,000 ÇöÀå 120,000¿ø ±â¾÷/±âŸ - ºñȸ¿ø »çÀü 140,000 ÇöÀå 170,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-07 HALLA 1&2 09:00~09:25 Precision medicine in NSCLC: Current interpretation of biomarkers from NGS Myung-Ju AHN(Samsung Medical Center Korea)
±³À°½Ã°£ 11-07 HALLA 1&2 09:25~09:50 Precision medicine in advanced prostate cancer Emmanuel S. ANTONARAKIS(The Johns Hopkins University USA)
±³À°½Ã°£ 11-07 HALLA 1&2 09:50~10:15 Gastric cancer in the era of precision medicine Jeeyun LEE(Samsung Medical Center Korea)
±³À°½Ã°£ 11-07 HALLA 3 09:00~09:18 AI, big data and oncology Yoon Sup CHOI(DHP Korea)
±³À°½Ã°£ 11-07 HALLA 3 09:18~09:36 Artificial intelligence for lung cancer imaging Kyu-Hwan JUNG(Vuno Korea)
±³À°½Ã°£ 11-07 HALLA 3 09:36~09:54 AI technologies for diagnosis of rare genetic cancer Changwon KEUM(3 Billion Korea)
±³À°½Ã°£ 11-07 HALLA 3 09:54~10:15 Deep learning for cancer precision medicine Seong Eui HONG(Theragen Korea)
±³À°½Ã°£ 11-07 BAEKDU 1&2 09:00~09:25 Promises and challenges of immunotherapy Aung NAING(MD Anderson Cancer Center USA)
±³À°½Ã°£ 11-07 BAEKDU 1&2 09:25~09:50 Emerging immuno-oncology targets and combination therapies Cathy PIETANZA(MSD USA)
±³À°½Ã°£ 11-07 BAEKDU 1&2 09:50~10:15 CAR-T therapy for solid tumors Edmund K MOON(Hospital of the University of Pennsylvania USA)
±³À°½Ã°£ 11-07 BAEKDU 3 09:00~09:25 Targeted therapy and biomarkers in hepatocellular carcinoma Changhoon YOO(Asan Medical Center Korea)
±³À°½Ã°£ 11-07 BAEKDU 3 09:25~09:50 Immunotherapy and biomarkers in hepatocellular carcinoma Hong Jae CHON(CHA Bundang Medical Center Korea)
±³À°½Ã°£ 11-07 BAEKDU 3 09:50~10:15 Future of clinical trials in hepatocellular carcinoma Stephen L. CHAN(The Chinese University of Hong Kong Hong Kong)
±³À°½Ã°£ 11-07 HALLA 1&2 10:30~11:10 Targeting DNA repair in Breast Cancer Andrew TUTT(The Institute of Cancer Research UK)
±³À°½Ã°£ 11-07 HALLA 1&2 11:10~11:50 The VHL tumor suppressor gene: Insights into oxygen sensing and cancer William G. KAELIN Jr.(Dana-Farber Cancer Institute USA)
±³À°½Ã°£ 11-07 HALLA 1&2 11:50~12:30 New Horizon of Neoadjuvant and Adjuvant Treatment in HER2-positive Breast Cancer Yeon Hee PARK(Samsung Medical Center Korea)
±³À°½Ã°£ 11-07 BAEKDU 1&2 11:50~12:30 New perspectives for the future treatment option in non small cell lung cancer Natasha B. LEIGHL(Princess Margaret Cancer Centre Canada)
ÈÞ½Ä 11-07 12:30~12:50 Break ()
±³À°½Ã°£ 11-07 HALLA 1&2 12:50~13:20 How to accept my manuscript to the high impact journal? Alex A. ADJEI(Mayo Clinic USA)
±³À°½Ã°£ 11-07 HALLA 1&2 13:20~13:50 Doing great research and writing great papers in high impact journals Jeong Ho LEE(KAIST Korea)
±³À°½Ã°£ 11-07 BAEKDU 1&2 12:50~13:10 Immune checkpoint inhibitors Jung Ae SEO(National Cancer Center Korea)
±³À°½Ã°£ 11-07 BAEKDU 1&2 13:10~13:30 Identification and management of toxicities related to immuno-oncologic therapy Juhyang CHEON(Yeungnam University Hospital Korea)
±³À°½Ã°£ 11-07 BAEKDU 1&2 13:30~13:50 Oncology pharmacist¡¯s role in immuno-oncologic therapy Soyeon HONG(Seoul National University Bundang Hospital Korea)
±³À°½Ã°£ 11-07 HALLA 3 14:10~14:40 STING signaling regulates immune-vascular crosstalk to enhance anti-tumor immunity Chan KIM(CHA Bundang Medical Center Korea)
±³À°½Ã°£ 11-07 HALLA 3 14:40~15:10 Immune surveillance and the role of the endogenous angiogenesis inhibitors thrombospondin-1 and endostatin in tumor immunity Sandra RYEOM(UPENN USA)
±³À°½Ã°£ 11-07 HALLA 3 15:10~15:40 Leverages advanced technologies to investigate microbiomes and their clinical impact Julia OH(The Jackson Laboratory USA)
±³À°½Ã°£ 11-07 HALLA 1&2 14:10~14:35 Precision genomics-based patients¡¯ care - ASCO¡¯s TAPUR study Edward Sanghyun KIM(Levine Cancer Institute USA)
±³À°½Ã°£ 11-07 HALLA 1&2 14:35~15:00 Clinical applications of NGS in Korea Tae-You KIM(Seoul National University Hospital Korea)
±³À°½Ã°£ 11-07 HALLA 1&2 15:00~15:25 Global collaboration in genomic data sharing and use Subha MADHAVAN(Georgetown University USA)
Åä·Ð 11-07 HALLA 1&2 15:25~15:40 Q&A ()
±³À°½Ã°£ 11-07 BAEKDU 1&2 14:10~14:40 Radiotherapy and Immunotherapy - New strategy for better outcome Adam RABEN(Christiana Care Health System USA)
±³À°½Ã°£ 11-07 BAEKDU 1&2 14:40~15:05 Radiotherapy and Immunotherapy - On ongoing clinical trial Jin Ho KIM(Seoul National University Hospital Korea)
±³À°½Ã°£ 11-07 BAEKDU 1&2 15:05~15:30 Toxicities of the combination of radiotherapy and immunotherapy Keun-Wook LEE(Seoul National University Bundang Hospital Korea)
Åä·Ð 11-07 BAEKDU 1&2 15:30~15:40 Q&A ()
±³À°½Ã°£ 11-07 BAEKDU 3 14:10~14:32 Principles of clinical advances of molecular targeted agent Moon Ki CHOI(National Cancer Center Korea)
±³À°½Ã°£ 11-07 BAEKDU 3 14:32~14:55 Principles of clinical advances of I-O Eun Joo KANG(Korea University Guro Hospital Korea)
±³À°½Ã°£ 11-07 BAEKDU 3 14:55~15:17 Management of molecular targeted agent-related AEs Gyeong-Won LEE(Gyeongsang National University Hospital Korea)
±³À°½Ã°£ 11-07 BAEKDU 3 15:17~15:40 Management of immune-related AEs Yun-Gyoo LEE(Kangbuk Samsung Hospital Korea)
±³À°½Ã°£ 11-07 HALLA 3 16:00~16:30 Development of CDK4/6 inhibitor for solid tumor Richard FINN(UCLA USA)
±³À°½Ã°£ 11-07 HALLA 3 16:30~17:00 Genetic landscape of hepatitis B virus–associated diffuse large B-cell lymphoma: Insights for novel targeted therapies Qiang PAN-HAMMARSTRÖM(Karolinska Institutet Sweden)
±³À°½Ã°£ 11-07 HALLA 3 17:00~17:30 Genomic Predictors of Disease Progression in Gastrointestinal Cancer Patrick TAN(Duke-NUS Medical School Singapore)
±³À°½Ã°£ 11-07 BAEKDU 1&2 16:00~16:20 The role of PARPi in ovarian cancer Keun Ho LEE(Seoul St. Mary¡¯s Hospital Korea)
±³À°½Ã°£ 11-07 BAEKDU 1&2 16:20~16:40 IO for ovarian cancer Gun Min KIM(Yonsei Cancer Center Korea)
±³À°½Ã°£ 11-07 BAEKDU 1&2 16:40~17:00 Combination of PARP inhibitors and Immune checkpoint inhibitors in ovarian cancer Jung-Min LEE(National Cancer Institute USA)
±³À°½Ã°£ 11-07 BAEKDU 1&2 17:00~17:20 International collaboration in GY cancer clinical research Elise C. KOHN(National Cancer Institute USA)
Åä·Ð 11-07 BAEKDU 1&2 17:20~17:30 Q&A ()
±³À°½Ã°£ 11-07 HALLA 1&2 16:00~16:25 Integrated precision medicine platform for data-sharing in USA Peter Goodhand(Global Alliance for Genomics and Health Canada)
±³À°½Ã°£ 11-07 HALLA 1&2 16:25~16:50 How can we incorporate NGS data-sharing platform for precision medicine in Korea? Woong Yang PARK(Samsung Medical Center Korea)
±³À°½Ã°£ 11-07 HALLA 1&2 16:50~17:15 KSMO-KCSG Korean precision medicine networking group initiative* KSMO: Korean Society of Medical Oncology, KCSG: Korean Cancer Study Group Jee Hyun KIM(Seoul National University Bundang Hospital Korea)
Åä·Ð 11-07 HALLA 1&2 17:15~17:30 Q&A ()
±³À°½Ã°£ 11-07 BAEKDU 3 16:00~16:05 ¿ÀÇÁ´× ¹× ¿¬ÀÚ¼Ò°³ Bong-Seog KIM(vhs medical center Korea)
±³À°½Ã°£ 11-07 BAEKDU 3 16:05~16:25 ±¹³» »óȲ ¼³¸í Dae Ho LEE(Asan Medical Center Korea)
±³À°½Ã°£ 11-07 BAEKDU 3 16:25~17:10 ¿µ±¹ »ç·Ê ¼Ò°³ TBD()
±³À°½Ã°£ 11-07 BAEKDU 3 17:10~17:55 ¹Ì±¹ »ç·Ê ¼Ò°³ CMS(Center for Medicare and Medicaid Services (CMS) USA)
Åä·Ð 11-07 BAEKDU 3 17:55~18:30 ÆгΠÅäÀÇ ¿¬»ç ¸ðµÎ()
±³À°½Ã°£ 11-07 HALLA 1 17:30~18:00 Recent clinical trials in adjuvant therapy for resected pancreatic cancer Dong-Hoe KOO(Kangbuk Samsung Hospital Korea)
±³À°½Ã°£ 11-07 HALLA 1 18:00~18:30 FOLFIRINOX in localized pancreatic cancer: It Changhoon YOO(Asan Medical Center Korea)
±³À°½Ã°£ 11-07 HALLA 2 17:30~17:50 From clinical trials to practice: CDK4/6 inhibitors for HR+ HER2- mBC treatment Richard FINN(UCLA USA)
±³À°½Ã°£ 11-07 HALLA 2 17:50~18:10 CDK4/6 inhibitors in future directions: understanding resistance & next sequence of therapies Kyong Hwa PARK(Korea University Anam Hospital Korea)
±³À°½Ã°£ 11-07 HALLA 2 18:10~18:30 Current unmet needs in TNBC and and evolving therapeutic strategies Andrew TUTT(The Institute of Cancer Research UK)
±³À°½Ã°£ 11-07 HALLA 3 17:30~18:00 Targeting BRAF V600E NSCLC Se Hoon LEE(Samsung Medical Center Korea)
±³À°½Ã°£ 11-07 HALLA 3 18:00~18:30 Optimizing treatment of neuroendocrine tumor in lung Shin-kyo YOON(Asan Medical Center Korea)
±³À°½Ã°£ 11-07 BAEKDU 1 17:30~18:00 Clinical benefit of ramucirumab as second-line therapy in advanced gastric cancer Minkyu JUNG(Yonsei Cancer Center Korea)
±³À°½Ã°£ 11-07 BAEKDU 1 18:00~18:30 Role of Anti-angiogenic agents in mCRC and Clinical practice in Japan Akitaka MAKIYAMA(Japan Community Healthcare Organization Kyushu Hospital Japan)
±³À°½Ã°£ 11-07 BAEKDU 2 17:30~17:50 Assessment, management, and barriers of breakthrough cancer pain: a nationwide study in Korea Su-Jin KOH(Ulsan University Hospital Korea)
±³À°½Ã°£ 11-07 BAEKDU 2 17:50~18:10 Individualized Treatment Strategies for Breakthrough Cancer Pain Seonghoon SHIN(Kosin University Gospel Hospital Korea)
±³À°½Ã°£ 11-07 BAEKDU 2 18:10~18:30 BTcP management; real world practice (including Abstral case review) David Hui(The University of Texas MD Anderson Cancer Center USA)
±³À°½Ã°£ 11-07 BAEKJE 17:30~18:00 Elevating the Treatment Paradigm with Nivolumab in NSCLC Young Joo MIN(Ulsan University Hospital Korea)
±³À°½Ã°£ 11-07 BAEKJE 18:00~18:30 Rethinking the management of Advanced RCC in an Evolving Therapeutic Landscape Chan KIM(CHA Bundang Medical Center Korea)